Mesothelioma physicians also felt hope. Mesothelioma is a rare yet fatal form of lung cancer. In most cases, the diagnosis comes in the later stages because of the latency period of asbestos exposure. The disease doesn’t come to light until 20 to 40 years down the road.
However, many physicians are hoping that the new test can not only detect lung cancer but to also detect mesothelioma. This test would allow for early detection, giving patients with mesothelioma a longer prognosis, potentially even helping physicians and researchers find a cure.
More About the New Test
The lung test is Oncimmune’s EarlyCDT®. The lung test primarily focuses on lung cancer, but not so much mesothelioma. The randomized controlled trial tested 12,209 people in Scotland and showed that those with high risks of developing lung cancer could have the disease detected much sooner with the blood test.
The test detects the body’s immune system activities.
Based on the studies, the test could detect cancer four or more years earlier than the typical resources used for diagnosing lung cancer.
Hope for Mesothelioma Patients
The prognosis associated with mesothelioma patients is hardly ever long. The disease usually shows when it’s too late to provide proper treatment. However, with the ability to detect an active immune system, there may be hopes to detect mesothelioma in its earlier stages—something that has not happened up to this point.
Early detection can also mean patients with mesothelioma can fully exercise their legal rights to hold negligent parties accountable. Those who suffer can take legal action against the parties responsible for asbestos exposure.
Our mesothelioma lawyers are here to help. You can count on Shrader & Associates to be by your side throughout the process and help you understand what rights you have moving forward.
Call our firm today at (713) 787-3733.